No Data
Research and development innovation, business cultivation, international perspective, examining the value growth logic of Chaoke Ophthalmology (6622.HK).
Over the next two years, Zhaoke Ophthalmology may usher in a period of intensive performance outbreaks.
Understanding the midterm performance of Meitu Eye Care (06622.HK) in 2024 in one picture.
On August 29, MediLink-Bev(06622.HK) announced its 2024 interim performance. Specific performance details will be explained below with a chart.
ZHAOKE OPHTH-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
MegaMedical-B (06622.HK) will hold a board of directors meeting on August 29 to approve the interim performance.
On August 16, Glorious Sun Ophthalmic (6622.HK) announced that the board of directors will hold a meeting on August 29, 2024 to approve the midterm performance of the company and its subsidiaries for the six months ending June 30, 2024 and to publish its announcement.
ZHAOKE OPHTH-B: NOTICE OF BOARD MEETING
Zhaoke Ophthalmology Expects Losses to Shrink in H1
No Data
